Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 28 resultados

SEARCH: Synthetic hEalthcare dAta goveRnanCe Hub AMGEN participó en un HORIZON EUROPE: HORIZON-JU-IHI-2023-05 The objectives of SEARCH are truly ground-breaking, seeking to enable extensive data aggregation and analysis while safeguarding the integri...
2024-09-13 - 2028-09-30 | Financiado

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence AMGEN participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

MOBILISE-D: Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement AMGEN participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing...
2019-03-22 - 2024-06-30 | Financiado

ITCC-P4: ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 AMGEN participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant s...
2017-05-18 - 2023-12-31 | Financiado

DO-IT: Big Data for Better Outcomes Policy Innovation and Healthcare System Transformation Sofia ref. 1... AMGEN participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage The overall goal of the Big Data for Better Outcomes (BD4BO) programme is to facilitate the use of ‘big data’ to promote the development of...
2017-01-30 - 2019-01-31 | Financiado

HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... AMGEN participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado

ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach... AMGEN participó en un H2020: H2020-JTI-IMI2-2015-04-two-stage-Master Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado

EPAD: European Prevention of Alzheimer’s Dementia Consortium AMGEN participó en un FP6: Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression...
2015-01-01 - 2019-12-31 | Financiado

WEB-RADR: Recognising Adverse Drug Reactions AMGEN participó en un FP6: WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. To...
2014-09-01 - 2017-12-31 | Financiado

GETREAL: Incorporating real-life clinical data into drug development AMGEN participó en un FP6: When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and effica...
2013-10-01 - 2017-03-31 | Financiado

EMIF: European Medical Information Framework AMGEN participó en un FP6: In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected,...
2013-01-01 - 2018-06-30 | Financiado

QUIC-CONCEPT: QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy AMGEN participó en un FP6: The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proli...
2011-09-01 - 2018-06-30 | Financiado

EHR4CR: Electronic Health Record systems for Clinical Research AMGEN participó en un FP6: Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost press...
2011-03-01 - 2016-02-29 | Financiado

U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes AMGEN participó en un FP6: RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado

EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology AMGEN participó en un FP6: The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
2009-09-01 - 2016-06-30 | Financiado

SAFE-T: SAFER AND FASTER EVIDENCE-BASED TRANSLATION AMGEN participó en un FP6: The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-...
2009-06-15 - 2015-06-14 | Financiado

GETREAL: Incorporating real life clinical data into drug development AMGEN participó en un FP7: When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and effica...
Financiado

EMIF: European Medical Information Framework AMGEN participó en un FP7: In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected,...
Financiado

U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes AMGEN participó en un FP7: Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma thi...
Financiado

EPAD: European Prevention of Alzheimer s Dementia Consortium AMGEN participó en un FP7: Background: The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progressio...
Financiado